News & Events

News Releases

Nobias Therapeutics Secures Preliminary FDA Alignment on Registrational Endpoints for NB-001 for Treatment of 22q11.2 Deletion Syndrome
June 16, 2025

FDA Grants Rare Pediatric Disease and Orphan Drug Designations to Nobias Therapeutics for the Treatment of 22q11.2 Deletion Syndrome
December 5, 2024

Nobias Therapeutics Announces Strategic Focus and New Leadership
November 14, 2024

Nobias Therapeutics Joins NVIDIA Inception Program for Startups
April 16, 2024

Nobias Therapeutics Announces Phase 2 Clinical Trial Results for NB-001 at 52nd Child Neurology Society Annual Meeting
October 10, 2023

Nobias Therapeutics Announces Acceptance of Late-Breaking Abstract and Presentation of Phase 2 Clinical Data for NB-001 at 52nd Child Neurology Society Annual Meeting
September 20, 2023

Events

NORD Breakthrough Summit
Washington, DC
October 19 – October 21, 2025

LSX World Congress USA
Boston, MA
September 16 – September 17, 2025

Pathways to Understanding 22q11.2 Copy Number Variants & The World View on 22q Family Conference 
Philadelphia, PA
September 4 – September 6, 2025

BIO International Convention
Boston, MA
June 16 – June 19, 2025

NORD Rare Disease Scientific Symposium
Washington, DC
June 2 – June 3, 2025

Society of Biological Psychiatry
Toronto, ON
April 24 – April 26, 2025

JPM Week
San Francisco, CA
January 13 – January 15, 2025

Sachs 8th Annual Neuroscience Innovation Forum
San Francisco, CA
January 12, 2025

Investival Showcase / London Life Sciences Week
London, UK
November 18, 2024

13th Biennial International 22q11.2 Scientific Meeting
Óbidos, Portugal
July 16 – July 18, 2024
• Presented full results of Nobias’ Ph 2 study of NB-001 for the treatment of the neuropsychiatric symptoms of 22q11DS

BIO International Convention 2024
San Diego, CA
June 3 – June 6, 2024

Biotech Showcase 2024
San Francisco, CA
January 8 – January 10, 2024